A Multicenter Randomized Clinical Trial Evaluating Interleukin-2 Activated Hematopoietic Stem Cell Transplantation and Post-transplant IL-2 for High Risk Breast Cancer Patients
Claudine Isaacs(Georgetown University), Marc E. Lippman(Georgetown University), Karen K. Ballen(University of Virginia Health System), Ellen M. Areman, Daniel F. Hayes(University of Michigan–Ann Arbor), Herbert B. Herscowitz(Georgetown University), Edmund A. Gehan(Georgetown University), Rebecca Slack, Ralph V. Boccia(Center for Cancer and Blood Disorders), Ruthie Kramer(Vince Lombardi Cancer Clinic)
Cited by 3
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
|Journal of neurosurgery|1978|1.7k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k